Medipal Holdings Corp

Common Name
Medipal Holdings
Country
Japan
Sector
Healthcare
Industry
Medical Distribution
Employees
13,061
Ticker
7459
Exchange
TOKYO STOCK EXCHANGE
Description
Medipal Holdings Corp is a leading company in Japan's pharmaceutical distribution industry. As a comprehensive pharmaceutical wholesaler, its primary function is to ensure the efficient distribution a...

Medipal Holdings's GHG Emissions Data Preview

In 2023, Medipal Holdings completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).

Medipal Holdings has also provided a category-level breakdown for 11 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.

Metric (tCO2e)2023202220212020 - 2017
Total Scope 1
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Scope 2
Unspecified Calculation Method
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Scope 3
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
b
Copy restricted. Please purchase to unlock this data.
b
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Download Data

Verified Sources Behind Medipal Holdings’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Medipal Holdings’s data sources below and access millions more through our Disclosure Search.

a. Medipal Holdings's Integrated Report 2023
a. Medipal Holdings's Integrated Report 2023
b. Medipal Holdings's Integrated Report 2022
b. Medipal Holdings's Integrated Report 2022

Insights into Medipal Holdings's Operational Emissions

In 2023, the total operational greenhouse gas (GHG) emissions of Medipal Holdings amounted to 74,991 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a

Compared to 2022, the total operational greenhouse gas (GHG) emissions of Medipal Holdings decreased by 1.44%, showing that the company has made progress in taking action to reduce the climate impact of its operations. a

Medipal Holdings's Scope 1 Emissions Over Time

20182019202020212022202309.5 k19 k28.5 k38 ktCO2e-2%-6%-2%-7%-6%
  • Total Scope 1
  • Year-over-Year Change

What are Medipal Holdings's Scope 1 emissions?

In 2023, the total Scope 1 emissions of Medipal Holdings were 28,439 metric tons of CO₂ equivalent (tCO₂e). a

Has Medipal Holdings reduced its Scope 1 emissions over time?

Since 2018, Medipal Holdings's Scope 1 emissions have decreased by 21.1%, reflecting a declining long-term trend in Scope 1 emissions over time. a b

Compared to the previous year (2022), Medipal Holdings's Scope 1 emissions decreased by 5.81%, highlighting the company's efforts to lower direct emissions from assets it owns or controls. a

What are Medipal Holdings's Scope 2 emissions?

In 2023, Medipal Holdings reported Scope 2 greenhouse gas (GHG) emissions of 46,552 tCO₂e without specifying the calculation method. a

Has Medipal Holdings reduced its Scope 2 emissions over time?

Since 2018, Medipal Holdings's Scope 2 greenhouse gas (GHG) emissions ( Unspecified Calculation Method) have decreased by 11.49%, reflecting a declining long-term trend in Scope 2 emissions over time. a b

Compared to the previous year (2022), Medipal Holdings's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Medipal Holdings 's emissions have plateaued with no significant change in its energy consumption footprint. a

What methodology does Medipal Holdings use for Scope 2 reporting?

In 2023, Medipal Holdings reported its Scope 2 emissions using an unspecified methodology. a

Medipal Holdings's Scope 2 Emissions Over Time

201820192020202120222023015 k30 k45 k60 ktCO2e
  • Total Scope 2 (Unspecified Calculation Method)

Insights into Medipal Holdings's Value Chain Emissions

In 2023, Medipal Holdings reported 14,255,621 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a

The 2023 disclosure of Medipal Holdings includes a breakdown across 11 of the 15 Scope 3 categories defined by the GHG Protocol, up from 1 in 2022, reflecting improved emissions accounting practices and greater transparency across the company's value chain a

Medipal Holdings's Scope 3 Emissions Over Time

20182019202020212022202304 M8 M12 M16 MtCO2e+5%+5%-3%+12%+36562%
  • Total Scope 3
  • Year-over-Year Change

What are Medipal Holdings's Scope 3 emissions?

In 2023, Medipal Holdings reported total Scope 3 emissions of 14,255,621 metric tons of CO₂ equivalent (tCO₂e). a

Approximately 95.68% of these emissions originated from upstream activities such as purchased goods and capital goods, while 4.32% came from downstream activities like product use, distribution, and end-of-life treatment. a

Has Medipal Holdings reduced its Scope 3 emissions over time?

Since 2018, Medipal Holdings's Scope 3 emissions have increased by 43,688%, reflecting a rising long-term trend in Scope 3 emissions over time. a b

Compared to the previous year (2022), Medipal Holdings's Scope 3 emissions increased by 36,561.92%, suggesting that the company faced challenges in reducing emissions across its value chain. a b

What categories of Scope 3 emissions does Medipal Holdings disclose?

In 2023, Medipal Holdings reported emissions for 11 out of the 15 Scope 3 categories defined by the GHG Protocol. a

This reflects a high level of granularity and transparency in the company's emissions reporting.

What are the main sources of Medipal Holdings's Scope 3 emissions?

In 2023, the largest contributors to Medipal Holdings's Scope 3 emissions were: a

  • Purchased Goods and Services (Cat. 1): 13,426,666 tCO₂e (94.19%)
  • End-of-Life Treatment of Sold Products (Cat. 12): 581,582 tCO₂e (4.08%)
  • Upstream Transportation and Distribution (Cat. 4): 110,073 tCO₂e (0.77%)

Medipal Holdings's Scope 3 Emissions by Categories

Purchased Goods andServices (Cat. 1)(94.2%)End-of-LifeTreatment of SoldProducts (Cat. 12)(4.1%)

Insights into Medipal Holdings’s GHG Emissions Intensity Compared to Industry Peers

In 2023, Medipal Holdings reported Scope 1 greenhouse gas (GHG) emissions of 28,439 tCO₂e and total revenues of USD 25,225 millions. This translates into an emissions intensity of 1.13 tCO₂e per millions USD. a

Medipal Holdings's Scope 1 Emissions Intensity Compared to Peers

501,00020,000200,0005,000,000Scope 1 Emissions (tCO2e)505002,00010,00050,000Revenues (Millions of USD)SNMAs OneYear: 2024Scope 1: 165 tCO2eRevenue: $M 631Scope 1 Intensity: 0.26 tCO2e/$MHisamitsu PharmaceuticalYear: 2022Scope 1: 7,862 tCO2eRevenue: $M 1,040Scope 1 Intensity: 7.56 tCO2e/$MSawai Group HoldingsYear: 2023Scope 1: 19,500 tCO2eRevenue: $M 1,229Scope 1 Intensity: 15.87 tCO2e/$MNihon KohdenYear: 2023Scope 1: 4,250 tCO2eRevenue: $M 1,551Scope 1 Intensity: 2.74 tCO2e/$MPeptiDreamYear: 2023Scope 1: 3,156 tCO2eRevenue: $M 203Scope 1 Intensity: 15.55 tCO2e/$MSundrugYear: 2024Scope 1: 22,197 tCO2eRevenue: $M 4,964Scope 1 Intensity: 4.47 tCO2e/$MSanten PharmaceuticalYear: 2024Scope 1: 17,372 tCO2eRevenue: $M 1,994Scope 1 Intensity: 8.71 tCO2e/$MH.U. Group HoldingsYear: 2022Scope 1: 13,418 tCO2eRevenue: $M 2,237Scope 1 Intensity: 6.00 tCO2e/$MSysmexYear: 2024Scope 1: 13,449 tCO2eRevenue: $M 3,047Scope 1 Intensity: 4.41 tCO2e/$MSSSugi HoldingsYear: 2023Scope 1: 1,531 tCO2eRevenue: $M 4,898Scope 1 Intensity: 0.31 tCO2e/$MOno PharmaceuticalYear: 2024Scope 1: 8,100 tCO2eRevenue: $M 3,319Scope 1 Intensity: 2.44 tCO2e/$MMatsukiyoCocokara & CoYear: 2023Scope 1: 1,764 tCO2eRevenue: $M 7,142Scope 1 Intensity: 0.25 tCO2e/$MChugai PharmaceuticalYear: 2024Scope 1: 51,143 tCO2eRevenue: $M 7,456Scope 1 Intensity: 6.86 tCO2e/$MSuzukenYear: 2023Scope 1: 26,491 tCO2eRevenue: $M 17,378Scope 1 Intensity: 1.52 tCO2e/$MTsuruha HoldingsYear: 2023Scope 1: 3,424 tCO2eRevenue: $M 6,940Scope 1 Intensity: 0.49 tCO2e/$MOtsuka HoldingsYear: 2021Scope 1: 1,030,000 tCO2eRevenue: $M 13,021Scope 1 Intensity: 79.10 tCO2e/$MSMSYear: 2023Scope 1: 220 tCO2eRevenue: $M 343Scope 1 Intensity: 0.64 tCO2e/$MAstellas PharmaYear: 2023Scope 1: 59,203 tCO2eRevenue: $M 11,401Scope 1 Intensity: 5.19 tCO2e/$MTsumura & CoYear: 2021Scope 1: 39,385 tCO2eRevenue: $M 1,055Scope 1 Intensity: 37.32 tCO2e/$MDaiichi SankyoYear: 2024Scope 1: 91,836 tCO2eRevenue: $M 10,576Scope 1 Intensity: 8.68 tCO2e/$MNNNippon ShinyakuYear: 2023Scope 1: 4,366 tCO2eRevenue: $M 1,082Scope 1 Intensity: 4.03 tCO2e/$MAlfresa HoldingsYear: 2023Scope 1: 32,399 tCO2eRevenue: $M 20,241Scope 1 Intensity: 1.60 tCO2e/$MKyowa KirinYear: 2024Scope 1: 16,133 tCO2eRevenue: $M 3,157Scope 1 Intensity: 5.11 tCO2e/$MSumitomo PharmaYear: 2023Scope 1: 27,093 tCO2eRevenue: $M 4,171Scope 1 Intensity: 6.50 tCO2e/$MMMMedipal HoldingsYear: 2023Scope 1: 28,439 tCO2eRevenue: $M 25,225Scope 1 Intensity: 1.13 tCO2e/$M

How does Medipal Holdings's GHG emissions intensity compare to its peers?

In 2023, Medipal Holdings reported a Scope 1 emissions intensity of 1.13 tCO₂e per millions USD. Compared to the peer group median of 4.79 , this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors. a

Where does Medipal Holdings rank on GHG emissions intensity within its industry?

In 2023, Medipal Holdings ranked 6 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a

Medipal Holdings is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency. a

Insights into Medipal Holdings's Total Carbon Footprint

In 2023, Medipal Holdings reported a total carbon footprint of 14,330,612 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 12,364.87% increase compared to 2022, suggesting a rise in emissions across its operations or value chain. a b

The largest contributor to Medipal Holdings's total carbon footprint was Scope 3 emissions, accounting for 99.48% of the company's total carbon footprint, followed by Scope 2 emissions at 0.32%. a

Want Full Access to Medipal Holdings's GHG Emissions Dataset?
Sign Up